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Abstract 
The term Gluten Related Disorders (GRD) denotes a spectrum of diverse 
immune mediated diseases triggered by the ingestion of gluten (protein found 
in wheat, barley and rye). Coeliac disease (CD) or gluten sensitive 
enteropathy is the most recognised and studied entity within GRD. 
Extraintestinal manifestations, are gaining recognition and are increasingly the 
subject of further studies as they may hold the key to unravelling the 
pathophysiology of GRD. Such manifestations include skin involvement in the 
form of dermatitis herpetiformis (DH) and neurological dysfunction (eg gluten 
ataxia and gluten neuropathy). Furthermore the recent concept of 
extraintestinal manifestations without enteropathy (termed Non-Coeliac 
Gluten Sensitivity-NCGS) has become accepted as part of the same 
spectrum. In this chapter we review the neurological manifestations in GRD, 
discuss recent advances in diagnosis, and possible pathophysiological 
mechanisms. 
 
Introduction 
Coeliac Disease (CD) was first described by the Greek doctor Aretaeus 
the Cappadocian, in 100 AD. Long time after, Samuel Gee published his 
lecture (Gee, 1888) “on the coeliac affection” in which he described the classic 
presentation of the disease in children. The aetiological agent remained 
obscure until the observations of Willem Dicke, a Dutch paediatrician, in 1953 
of “the presence in wheat, of a factor having a deleterious effect in cases of 
coeliac disease” (Dicke et al., 1953). The introduction of endoscopy and small 
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bowel biopsy in the 50’s confirmed the bowel as the principal organ involved  
(Paulley, 1953). Such biopsies demonstrated for the first time the typical 
histological abnormalities that now define gluten sensitive enteropathy: villous 
atrophy, crypt hyperplasia and increased intraepithelial lymphocytes.  
 The first evidence of gluten sensitivity related extraintestinal 
manifestations became apparent in 1963 when a group of dermatologists 
published the interesting observation that dermatitis herpetiformis, an itchy 
vesicular rash, was in fact a form of gluten related dermatopathy sharing the 
same small bowel pathology, but less prominent or even no gastrointestinal 
symptoms (Marks et al., 1963). The only reason why small bowel biopsies 
were done in this group of patients was the observation of persistently low 
albumin suggestive of protein loss from the gut. 
 A small number of case reports of patients with presumed CD and 
neurological manifestations (Elders, 1925; Reed and Ash 1927; Woltman and 
Heck 1937) were published prior to the discovery of the aetiological agent and 
the introduction of small bowel biopsy. Such reports need to be treated with 
caution given that a diagnosis of CD in those patients was speculative.   
 The first comprehensive case series of neurological manifestations in 
the context of histologically confirmed CD was published in 1966 (Cooke and 
Thomas-Smith, 1966). This detailed clinical and pathology work described the 
range of neurological manifestations seen in 16 patients with established CD. 
Of interest was the fact that all patients had gait ataxia and some had 
peripheral neuropathy as well. The assumption was that such manifestations 
were nutritional. Indeed all of these patients were grossly malnourished and 
cachectic. Post-mortem data, however, demonstrated an inflammatory 
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process primarily affecting the cerebellum, but also involving other parts of the 
central and peripheral nervous systems, a finding that was in favour of an 
immune mediated pathogenesis.  
 Single and multiple case reports of patients with established CD who 
then developed neurological dysfunction continued to be published (Binder et 
al., 1967; Bundley, 1967; Morris et al., 1970; Coers et al., 1971; Kepes et al., 
1975; Coers et al., 1971; Kepes et al., 1975; Finelli et al., 1980; Kinney et al., 
1982; Ward and Murphy 1985; Lu et al., 1986; Kristoferitsch and Pointer, 
1987; Kaplan et al., 1988; Tison et al., 1989; Hermaszewski et al., 1991; Colin 
et al., 1991; Dick et al., 1995; Bhatia et al., 1995; Muller et al., 1996)  
Key findings from these reports were that ataxia and/or neuropathy were the 
commonest manifestations always seen in the context of established CD and 
almost always attributed to nutritional deficiencies. Some reports reported 
improvement of the neurological problems with adherence to a GFD whilst 
others did not. None of these reports however documented the strictness of 
adherence to the gluten free diet by regular serological testing. 
Thirty years after the first comprehensive case series on neurological 
manifestations of CD saw the publication of a study (Hadjivassiliou et al., 
1996) approaching the subject purely from a neurological perspective. This 
study investigated the prevalence of serological markers of gluten sensitivity 
(at the time, IgG and IgA antigliadin antibodies) in patients presenting with 
neurological dysfunction. The results demonstrated significantly higher 
prevalence of antigliadin antibodies (AGA) in the neurology group of patients 
with unclear diagnosis when compared to healthy blood donors and patients 
with a clear neurological diagnosis. Based on duodenal biopsies the study 
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showed that the prevalence of CD was 16 times higher than the prevalence of 
CD in the healthy population. This study sparked an interest for both 
neurologists and gastroenterologists in a possible link between sensitivity to 
gluten and neurological disease. 
 
Epidemiology of neurological manifestations 
There are now several epidemiological studies from Europe, America and a 
few from other continents demonstrating that the prevalence of CD in healthy 
individuals is on the increase (Catassi et al., 2014). Thus the prevalence of 
CD in the healthy population has been shown to be at least 1% (Sanders et 
al., 2003). There are no accurate figures of the prevalence of the neurological 
manifestations of gluten sensitivity in the general population. Some studies 
have concentrated on the prevalence of neurological dysfunction amongst 
patients with established CD. Figures of between 10% and 22.5% have been 
published (Holmes, 1997; Briani et al.,2008). Such figures are unlikely to be 
accurate because they are retrospective, derived solely from gastrointestinal 
clinics and concentrated exclusively on patients with the classic (ie 
gastrointestinal) CD presentation. Some of these studies also included 
neurological diseases that are highly unlikely to be gluten related (eg carpal 
tunnel syndrome, idiopathic Parkinson’s disease).  
Some estimates of prevalence can be made from patient populations 
attending specialist clinics although caution must be exercised in extrapolating 
these as they are inevitably affected by referral bias. For example, data 
collected from the Sheffield dedicated CD clinic (the biggest in the UK) and 
from the dedicated gluten sensitivity/neurology clinic (the only one in the UK) 
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suggested that for every 7 patients presenting to the gastroenterologist who 
are then diagnosed with CD, 2 patients present to the neurologist with 
neurological dysfunction leading to the diagnosis of CD (Hadjivassiliou et al., 
2010a). This ratio is likely to be an underestimate because it does not take 
into account those patients with neurological manifestations due to sensitivity 
to gluten that do not have enteropathy (NCGS). In fact, approximately two 
thirds of patients presenting with neurological dysfunction do not have 
enteropathy on duodenal biopsy. The authors believe that the prevalence of 
neurological dysfunction even in patients with CD presenting to 
gastroenterologists is likely to be much higher to what has been published if 
patients undergo rigorous neurological workup including MR spectroscopy of 
the cerebellum. Preliminary results from a prospective study using patients 
with newly diagnosed CD presenting to a gastroenterologist demonstrated 
that up to 50% of such patients have abnormal MR spectroscopy (low NAA/Cr 
ratios) of the cerebellum (Hadjivassiliou et al., 2013). One study in patients 
with established CD has shown such abnormalities in up to 80% of patients 
(Hadjivassiliou et al., 2011) whilst another study has shown that the 
prevalence of peripheral neuropathy in this group of patients was 23% 
(Luostarinen et al.,2003). The above figures are based on patients with CD. 
The frequency of neurological dysfunction in patients with NCGS is not 
known. Judging by the fact that 2/3 of the cohort of patients seen and 
assessed in a dedicated gluten/neurology clinic, Sheffield, UK have NCGS, it 
is likely that the prevalence of neurological cases with NCGS is even higher 
than those with CD.  
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Diagnosis of the spectrum of gluten related diseases 
The diagnosis of CD in the hands of an experienced gastroenterologist and 
gastrointestinal histopathologist can be relatively straightforward. CD is after 
all defined by the presence of an enteropathy (triad of villus atrophy, crypt 
hyperplasia and increased intraepithelial lymphocytes), usually a reliable gold 
standard. It is now, however accepted, that the presence of enteropathy is not 
a prerequisite for the diagnosis of GRD particularly for those patients where 
neurological or other extraintestinal manifestations are the presenting feature. 
Furthermore, the triad of the small bowel mucosal changes mentioned above 
are merely one part of the small bowel histological spectrum (Marsh 
classification) that ranges from a normal mucosa to a pre-lymphomatous state 
(Marsh, 1992). Given that the bowel histology in some cases (as per Marsh 
classification) can be normal, trying to define GRD using solely the bowel 
biopsies becomes problematic. Whilst serological testing has enhanced the 
ability to identify patients with enteropathy, none of these tests are 100% 
specific or sensitive (ref). For example, endomysial antibody (EMA) and anti-
transglutaminase-2 (TG2) IgA antibody detection are specific for the presence 
of an enteropathy. These markers are frequently negative in patients with 
neurological or other extraintestinal manifestations who do not have an 
enteropathy (Hadjivassiliou et al. 2008, 2013).  
 The majority of patients presenting with neurological manifestations 
have no gastrointestinal symptoms (ref). Even patients with CD may not have 
gastrointestinal symptoms. In patients without overt gastrointestinal 
involvement (enteropathy), serum antibodies to TG2 may be absent 
(Kaukinen et al., 2005). Patients with extraintestinal manifestations typically 
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have antibodies primarily reacting with different TG isozymes, TG3 in DH and 
TG6 in patients with gluten ataxia (Sardy et al., 2002; Hadjivassiliou et al, 
2008). Reaction of such antibodies with TG2 that takes the form of IgA 
deposits against TG2 in the intestinal mucosa occurs prior to overt changes in 
small intestinal morphology and sometimes even before the antibodies are 
detectable in serum (Korponay-Szabo et al, 2003). Such antibody deposits 
seem to be present in patients with neurological and other extraintestinal 
manifestations as well, and may therefore be diagnostically useful 
(Hadjivassiliou et al, 2006). However, this test is not readily available and 
requires experience in its interpretation. In practise for suspected neurological 
manifestations, it is best to perform serological tests for both IgA and IgG 
antibodies to TG2 (and if available anti-TG6 and anti-TG3) as well as IgG and 
IgA antibodies to gliadin. Endomysium antibodies are very specific for the 
detection of enteropathy, but they detect the same antigen (transglutaminase 
2) and have thus largely been replaced by TG2 antibody testing. Any 
differences between the 2 tests however are likely to be related to the 
different methodologies used (ELISA for TG2 vs immunofluorescence for the 
detection of EMA). The diagnosis of NCGS remains problematic by the 
absence of any biological markers. At the moment such diagnosis is based on 
symptomatic improvement after the introduction of a GFD and recurrence of 
symptoms on re-introduction of gluten in the diet. Antigliadin antibodies of the 
IgG type can be present in up to 25% of patients with NCGS attending 
gastroenterology clinics and such patients may also have increased 
intraepithelial lymphocytes (Volta et al.,2014).  
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 CD has a strong genetic predisposition whereby ~40% of the genetic 
load comes from MHC class II association (Hunt, 2008). In Caucasian 
populations more than 90% of CD patients carry the HLA DQ2, with the 
remaining having the HLA DQ8. A small number of CD patients do not belong 
into either of these groups but these have been shown to carry just one chain 
of the DQ2 heterodimer (Jabri and Sollid, 2009). HLA genetic testing is 
therefore another useful tool, particularly as unlike other serological tests it is 
not dependent on an immunological trigger. However, the HLA DQ genotype 
can be used only as a test of exclusion of CD as the risk genotype DQ2 is 
common in Caucasian and Asian populations and many carriers will never 
develop GRD. Furthermore patients with NCGS may not have the HLA DQ2 
or DQ8 (ref). Several genome wide association studies over the past decade 
have identified many non-HLA loci that each contribute a small amount of risk 
for celiac disease (Lundin and Sollid, 2014). Most of these additional genes 
are involved in immune functions and in fact, several risk loci are shared with 
other autoimmune conditions including ankylosing spondylitis, rheumatoid 
arthritis, type 1 diabetes and psoriasis. A recent study showed that including 
non-HLA variants in addition to HLA in the test for celiac disease risk 
improves the accuracy of disease prediction (Romanos et al., 2014). A bias 
for loci conferring risk for specific manifestations of GRD remains to be 
thoroughly investigated. 
 
 
 
The spectrum of gluten related neurological manifestations 
 
 
Gluten ataxia 
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Gluten ataxia (GA) is defined as idiopathic sporadic ataxia with positive 
serological markers for sensitivity to gluten (Hadjivassiliou et al, 2003). The 
original definition was based on the serological tests available at the time 
(antigliadin IgG and IgA antibodies). In a series of 1000 patients with 
progressive ataxia evaluated over a period of 20 years in Sheffield, UK, GA 
had a prevalence of 15% amongst all ataxias but as high as 41% amongst 
idiopathic sporadic ataxias. Using the same AGA assay the prevalence of 
positive AGA in genetically confirmed ataxias was 14/110 (13%), and in 
healthy volunteers 149/1200 (12%).  A number of studies looking at the 
prevalence of antigliadin antibodies in ataxias have been published 
(Hadjivassiliou et al., 1996; Pellecchia et al., 1999; Burk et al., 2001; Bushara 
et al., 2001; Luostarinen et al., 2001; Abele et al., 2002; Hadjivassiliou et al., 
2003; Abele et al., 2003; Ihara et al., 2006; Anheim et al., 2006) The 
variations in prevalence may relate to geographical differences in the 
prevalence of CD, referral bias, variability in the AGA assays used, patient 
selection (some studies included as idiopathic sporadic ataxia patients with 
cerebellar variant of multi-system atrophy), small number of patients studied 
and no controls. The common theme in the majority of these studies is the 
consistently high prevalence of AGA antibodies in sporadic ataxias when 
compared to healthy controls.  
GA usually presents with pure cerebellar ataxia or rarely ataxia in 
combination with myoclonus (see below), palatal tremor (Hadjivassiliou et al., 
2008), opsoclonus (Deconinck et al., 2006) or rarely, chorea (Pereira et al., 
2004). GA is usually of insidious onset with a mean age at onset of 53 years. 
Rarely the ataxia can be rapidly progressive mimicking paraneoplastic 
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cerebellar degeneration. Gaze-evoked nystagmus and other ocular signs of 
cerebellar dysfunction are common (80% of cases). All patients have gait 
ataxia and the majority have limb ataxia. Less than 10% of patients with GA 
will have any gastrointestinal symptoms but 40% will have evidence of 
enteropathy on biopsy.  
Serological diagnosis still relies on the presence of IgG and/or IgA 
antigliadin antibodies but more specific biomarkers have been identified. TG6 
antibodies have been found to be present in 73% of patients with idiopathic 
sporadic ataxia with positive AGA (Hadjivassiliou et al., 2008). Furthermore, 
32% of patients with idiopathic sporadic ataxia negative for other serological 
markers of sensitivity to gluten were found to be positive for TG6 
(Hadjivassiliou et al, 2013). This may suggest that the prevalence of gluten 
ataxia may even be higher than previously thought.  
 Patients with GA usually have evidence of cerebellar atrophy on MR 
imaging with particular predilection for the cerebellar vermis. MR 
spectroscopy of the vermis is abnormal in all patients with GA (low N-Acetyl 
Aspartate/Creatine ratio) with less prominent changes in the cerebellar 
hemispheres (ref). Even in patients with GA without cerebellar atrophy, MR 
spectroscopy is abnormal. MR spectroscopy is a useful monitoring tool. 
Patients who adhere to strict gluten free diet often have evidence of 
improvement of the NAA/Cr ratio within the vermis after a year on the diet. 
The response to treatment with a gluten-free diet depends on the 
duration of the ataxia prior to the diagnosis of sensitivity to gluten. Loss of 
Purkinje cells in the cerebellum, the end result of prolonged gluten exposure 
in patients with GA, is irreversible, therefore prompt treatment is more likely to 
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result in improvement or stabilisation of the ataxia. Whilst the benefits of a 
gluten-free diet in the treatment of patients with CD and DH have long been 
established, there are very few studies, mainly case reports, of the effect of 
gluten-free diet on the ataxia.   Most of these reports primarily concern patients 
with established CD who then develop ataxia (Pellecchia et al., 1999; 
Beversdorf et al., 1996; Hahn et al.,1998). These reports suggest overall 
favourable responsiveness to a gluten-free diet. A small, uncontrolled study 
and another case study looked at the use of intravenous immunoglobulins in 
the treatment of patients with GA with and without enteropathy (Bürk et al., 
2001, Sander et al., 2003;).  All patients improved. In all of these reports, strict 
adherence to the gluten-free diet was assumed and no serological evidence 
was provided.  The best marker of strict adherence to a gluten-free diet is 
serological evidence of elimination of gluten related antibodies. Only one 
systematic study of the effect of gluten-free diet on a cohort of patients 
presenting with ataxia, with or without an enteropathy, has been published 
(Hadjivassiliou et al., 2003). This study also reported serological evidence of 
elimination of the antigliadin antibodies as a confirmation of strict adherence 
to the diet. Forty three patients with gluten ataxia were enrolled. Twenty six 
adhered strictly to the gluten-free diet, had serological evidence of elimination 
of antibodies and comprised the treatment group.  Fourteen patients refused 
the diet and comprised the control group.  Patient and control groups were 
matched at baseline for all variables (age, duration of ataxia etc). There was 
no significant difference in the baseline performance for each ataxia test 
between the two groups. There was significant improvement in performance 
in test scores and in the subjective global clinical impression scale in the 
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treatment group when compared to the control group. The improvement was 
apparent even after excluding patients with an enteropathy.  The study 
concluded that gluten-free diet is an effective treatment for GA.  
 The current recommendation is that patients presenting with idiopathic 
progressive cerebellar ataxia should be screened for sensitivity to gluten 
using antigliadin IgG and IgA, anti-TG2, anti-TG6  and endomysium 
antibodies (Hadjivassiliou et al., 2013). Patients positive for any of these 
antibodies with no alternative cause for their ataxia should be offered a strict 
gluten free diet with regular follow up to ensure that the antibodies are 
eliminated (usually takes 6 to 12 months). Stabilisation or even improvement 
of the ataxia at 1 year would be a strong indicator that the patient suffers from 
gluten ataxia. The commonest reason for lack of response is compliance with 
the diet. If patients on strict gluten free diet continue to progress, with or 
without elimination of antibodies, the use of immunosuppressive medication 
(mycophenolate) should be considered. Such cases are rare. 
 
Myoclonic ataxia and refractory coeliac disease 
In 1986 Lu and colleagues published two cases with action myoclonus, 
ataxia and CD who in addition had epilepsy (Lu et al., 1986). The authors 
provided electrophysiological evidence for the cortical origin of the myoclonus.  
Similar findings of action, stimulus sensitive, cortical myoclonus were 
subsequently reported in another patient (Tison et al., 1989). This patient had 
cortical reflex and action myoclonus resembling epilepsia partialis continua, 
with constant arrhythmic myoclonic activity in the right hypothenar muscles.  
Electrophysiology confirmed the cortical origin of the myoclonus.   
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A case series was published in 1995 reporting 4 patients with 
myoclonus and ataxia with electrophysiological evidence of stimulus sensitive 
myoclonus of cortical origin (Bhatia et al., 1995).  Pathology showed atrophy 
of the cerebellar hemispheres with Purkinje cell loss.  CD was diagnosed in all 
four, preceding the onset of the neurological manifestations by years. Such 
patients unlike those with gluten ataxia appear to be poorly responsive to 
gluten-free diet and follow a progressive course. The largest series published 
so far reported 9 patients (6 male, 3 female) with ataxia and asymmetrical 
irregular jerking (Sarrigiannis et al., 2014). The jerking affected one or more 
limbs and sometimes face and it was often stimulus sensitive. All patients 
later developed more widespread jerking. Six patients had a history of 
Jacksonian march and five had at least one secondarily generalised seizure. 
Electrophysiology showed evidence of cortical myoclonus.  Four had a 
phenotype of epilepsia partialis continua. There was clinical, imaging and/or 
pathological evidence of cerebellar involvement in all cases.  Eight patients 
adhered to a strict gluten-free diet with elimination of gluten-related 
antibodies, despite which there was still evidence of enteropathy in all thus 
suggestive of refractory celiac disease. One patient only just started the diet, 
2 died from enteropathy-associated lymphoma. Five patients were treated 
with mycophenolate and one in addition with rituximab and IV 
immunoglobulins.  Whilst their ataxia and enteropathy improved, the 
myoclonus remained the most disabling feature of their illness.  This was the 
first report to highlight the strong association of this unusual phenotype with 
refractory CD and in 2 of the cases enteropathy associated lymphoma.  
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Gluten neuropathy 
Up to 23% of patients with established CD on gluten-free diet have 
neurophysiological evidence of a peripheral neuropathy (Luostarinen et al., 
2003). A large population based study of over 84,000 patients with CD in 
Sweden found that CD was associated with polyneuropathy with a hazard 
ratio of 3.4 (Ludvigsson et al., 2007). In a UK based study, 34% of patients 
with otherwise idiopathic sporadic sensorimotor axonal length dependent 
neuropathy were found to have circulating AGA (Hadjivassiliou et al., 2006). 
Using anti-TG2 antibody an Italian study also found 21% of patients with 
peripheral neuropathy to be positive (Mata et al.,2006). Finally, in a tertiary 
referral centre in the USA, retrospective evaluation of patients with 
neuropathy showed the prevalence of CD to be between 2.5 and 8% as 
compared to 1% in the healthy population (Chin et al., 2003).  
 Gluten neuropathy is defined as otherwise idiopathic sporadic 
neuropathy with serological evidence of sensitivity to gluten. The commonest 
types are symmetrical sensorimotor axonal length dependent peripheral 
neuropathy and sensory ganglionopathy (Hadjivassiliou et al., 2010b). Other 
types of neuropathies have also been reported including asymmetrical 
neuropathy (Kelkar et al., 1996; Hadjivassiliou et al., 1997; Chin et al., 2006) 
small fibre neuropathy (Brannagan et al., 2005) and rarely pure motor 
neuropathy (Hadjivassiliou et al., 1997) or autonomic neuropathy (Gibbons 
and Freeman, 2005). Gluten neuropathy is slowly progressive with a mean 
age at onset of the neuropathy being 55 years (range 24 to 77) and a mean 
duration of 9 years (range 1 to 33). A third of the patients will have evidence 
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of enteropathy on biopsy but the presence or absence of an enteropathy does 
not influence the effect of a gluten-free diet (Hadjivassiliou et al., 2006). 
 Limited pathological data available from post-mortem examinations and 
nerve biopsies are consistent with an inflammatory aetiology (perivascular 
lymphocytic infiltration). Gluten-free diet has been shown to be beneficial in 
single and multiple case reports. The only systematic, controlled study of the 
effect of a gluten-free diet on 35 patients with gluten neuropathy, with regular 
serological monitoring of the adherence to the gluten-free diet, found 
significant improvement in the treated compared with the control group after 1 
year on gluten free diet (Hadjivassiliou et al., 2006). There was significant 
increase in the sural sensory action potential, the pre-defined primary 
endpoint, in the treatment group as well as subjective improvement of the 
neuropathic symptoms. Subgroup analysis showed that the capacity for 
recovery is less when the neuropathy is severe.  
Sensory ganglionopathy (sometimes also called neuronopathy) is an 
asymmetric form of pure sensory neuropathy where the pathology is within 
the dorsal root ganglia. It can be a paraneoplastic syndrome or related to 
Sjogren’s syndrome. It can also be seen in some inherited neurological 
illnesses such as Friedreich’s ataxia and mitochondrial diseases (POLG-1). 
Sensitivity to gluten has proven to be the commonest cause of sensory 
ganglionopathy (ref). In such cases, there is evidence of inflammatory 
infiltrates within the dorsal root ganglia. The disease progresses slowly if 
untreated but strict adherence to a gluten free diet may result in stabilisation 
or even improvement of the neuropathy irrespective of the presence of 
enteropathy (Hadjivassiliou et al., 2010b).  
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Headache and gluten sensitivity (gluten encephalopathy) 
Headache is a common feature in patients with GRD. The association 
was first reported in 2001 based in a series of 10 patients with GRD and 
headache who in addition had CNS white matter abnormalities on MRI scan 
(Hadjivassiliou et al., 2001). The term “gluten encephalopathy” was used to 
describe them. The headaches are usually episodic and intractable. They can 
mimic migraines but do not respond to the usual migraine medication. They 
characteristically resolve with the introduction of a gluten free diet. Some 
patients report a very strong association with ingestion of gluten. The white 
matter abnormalities are not always present but can be diffuse or focal. They 
do not always resolve following a gluten-free diet. The diet simply arrests 
progression of these changes but the white matter changes can be 
progressive if the patient does not adhere to a strict gluten free diet. Their 
distribution is more suggestive of a vascular rather than demyelinating 
aetiology. In a prospective study of patients newly diagnosed with CD 
frequency of intractable headaches was 44% (Hadjivassiliou et al., 2013) 
 In patients with migraine there is an overrepresentation of CD with a 
prevalence of 4.4% vs 0.4% in the control population (Gabrielli et al., 2003). 
Using PET brain imaging, a study on regional cerebral perfusion 
demonstrated that 73% of patients with CD not on a gluten-free diet, had at 
least one hypoperfused brain region as compared to 7% in healthy controls 
and in patients with CD on a gluten-free diet (Addolorato et al., 2004). Another 
study investigated the prevalence of white matter abnormalities in children 
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with CD and found that 20% of patients had such abnormalities (Kieslich et 
al., 2001).  
 Over the last 20 years we have encountered 100 patients with gluten 
encephalopathy, a figure that includes the initial 10 patients reported in the 
2001 series. Gluten encephalopathy does not always occur in isolation and 
such patients will often have additional neurological features such as ataxia. A 
study from the Mayo clinic emphasised the significant cognitive deficits 
encountered in 13 such patients (Hu et al., 2006). By comparison to gluten 
ataxia and gluten neuropathy there is a higher prevalence of enteropathy in 
patients with gluten encephalopathy (59/100), but the age at onset is the 
same. The observed improvement of the headaches and arrest of progression 
in the MRI brain abnormalities, suggest a causal link with gluten ingestion 
(Serratrice et al., 2003). Gluten encephalopathy represents a spectrum of 
clinical presentations with episodic headaches responsive to a gluten-free diet 
at one end, to severe debilitating headaches sometimes associated with focal 
neurological deficits. MRI findings range from normal to extensive white 
matter abnormalities. 
 
Epilepsy 
A link between epilepsy and CD was proposed as far back as 1978 
(Chapman et al., 1978; Fois et al., 1994; Cronin et al.,1998). Whilst studies 
examining the prevalence of CD amongst patients with epilepsy have 
suggested a prevalence of 1.2-2.3%, others failed to demonstrate an 
increased prevalence (Ranua et al., 2005). A more recent large (28,885 
subjects with CD) population-based cohort study showed that patients with 
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CD were at an increased risk of future epilepsy (HR=1.42). The absolute risk 
of future epilepsy in patients with CD was 92/100,000 person-years which 
equates to an excess risk of 27/100,000 person-years (Ludvigsson et al., 
2012). Most studies on the subject suffer from the same methodological 
problem of treating epilepsy as a homogeneous disorder. The only study that 
attempted to look at the prevalence of GRD in well characterised subgroups 
of patients with epilepsy found a significant association between AGA and 
temporal lobe epilepsy with hippocampal sclerosis (Paltola et al., 2009). Of 
interest are some case reports on patients with CD and epilepsy whose 
epilepsy improves following the introduction of gluten-free diet (Mavroudi et 
al., 2005; Harper et al., 2007). 
There is a particular form of focal epilepsy associated with occipital 
calcifications that appears to have a strong link with CD (Gobbi et al., 1992). 
This entity is common in Italy but rare in other countries. It tends to affect 
young patients (mean age 16 years) and in the majority the seizures are 
resistant to antiepileptic drugs. The pathogenesis of the cerebral calcifications 
remains unclear. An autopsy study showed that these depositions consisted 
of both calcium and silica, and microscopically were found in three main 
types: psammoma-like bodies without any identifiable relationship to cells, 
vessels or other structures; small granular deposition along small vessels; and 
focal scanty areas of calcium within neurons (Toti et al, 1996). As most of the 
reported cases are from Italy, Spain, and Argentina, it has been hypothesized 
that the syndrome of coeliac disease, epilepsy, and cerebral calcifications is 
“a genetic, non-inherited, ethnically and geographically restricted syndrome 
associated with environmental factors” (Gobbi, 2005). A case study of a 4 
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year old boy with refractory epilepsy, occipital calcifications and coeliac 
disease reported positive antibody binding to neurones and glia using indirect 
immunofluorescence. High levels of TG6 antibodies were found in the patients 
serum. After the introduction of gluten free diet the child became seizure free 
(Johnson et al., 2012).  
 
Myopathy 
This is a relatively rare neurological manifestation of GRD, first described by 
Henriksson et al. (1982). This study from Sweden reported that out of 76 
patients with suspected polymyositis investigated at a neuromuscular unit, 17 
had a history of gastrointestinal symptoms with evidence of malabsorption. 
Fourteen of these fulfilled the diagnostic criteria for polymyositis and of those 
5 were diagnosed with CD. A more recent study from Spain (Selva-
O’Callaghan et al, 2007) demonstrated the prevalence of AGA antibodies 
amongst patients with inflammatory myopathies to be 31%. This was 
accompanied by a higher prevalence of CD within the same population when 
compared to healthy controls.  
 A case series of 19 patients are based on what we have encountered 
in the gluten neurology clinic, Sheffield, UK over the last 20 years. Thirteen of 
these patients have been reported previously (Hadjivassiliou et al., 2007). 
Enteropathy was identified following duodenal biopsy in 11 of these patients. 
The mean age at onset of the myopathic symptoms was 54 years. Ten 
patients had predominantly proximal weakness, 6 patients had both proximal 
and distal weakness, and 4 patients had primarily distal weakness. Two 
patients had ataxia and neuropathy, and one patient had just neuropathy in 
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addition to the myopathy. Serum creatine kinase (CK) level ranged between 
normal to 4380 IU/L at presentation (normal, 25-190 IU/L). Inflammatory 
myopathy was the most common finding on neuropathological examination. 
Six patients received immunosuppressive treatment in addition to starting a 
gluten-free diet whereas the others went on a gluten-free diet only. In the 
majority of those patients who did not receive immunosuppressive treatment, 
there was clinical improvement of the myopathy with gluten-free diet, 
suggesting that the myopathy was aetiologically linked to the GRD. One 
patient developed a profound myopathy after inadvertently eating rye flour. He 
made a full recovery by re-establishing a strict gluten-free diet. Two patients 
had histological evidence of inclusion body myositis. It is interesting to note 
that inclusion body myositis shares the same HLA genetic predisposition with 
CD (ref). One patient was known to have CD already when he developed the 
myopathy. He was on gluten free diet already with negative serology for CD. 
Muscle biopsy showed an inflammatory myopathy and repeat duodenal 
biopsy showed a flat mucosa. Further immunohistological examination of the 
biopsy did not suggest refractory CD. The patient admitted the occasional 
dietary indiscretion. He underwent further dietary review and has been started 
on steroids with some clinical improvement. 
 
Myelopathy 
Clinical evidence of a myelopathy in the absence of vitamin B12 and other 
deficiencies (particularly copper) can be a rare manifestation of CD. It is 
usually associated with normal imaging of the spinal cord although cases of 
transverse myelitis like MR appearances have been encountered in our cohort 
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of patients. The neurological presentation often coincides with the diagnosis 
of CD. There have been some case reports of patients with neuromyelitis 
optica and sensitivity to gluten who have antibodies to aquaporin-4 (Jacob et 
al., 2005; Jarius et al., 2008). Such patients clearly have abnormal MRI of the 
spinal cord but the diagnosis of CD was only made at the time of their 
neurological presentation. Neuromyelitis optica and CD share the same HLA 
genetic susceptibility (HLA DQ2). There is very limited data on the effect of 
the diet on the likelihood of relapse of the disease particularly given the fact 
that most patients with neuromyelitis optica end up on long term 
immunosuppressive medication. 
 
Stiff-Man Syndrome 
Stiff-Man syndrome (SMS) is a rare autoimmune disease characterised by 
axial stiffness, painful spasms and positivity for anti-GAD. It has a strong 
association with other autoimmune diseases (eg IDDM, hypothyroidism). We 
have found a high prevalence of gluten related antibodies in patients with this 
condition over and above that expected from an association of 2 autoimmune 
diseases. The relapsing remitting nature of the condition makes a study of any 
responsiveness to gluten free diet difficult. There is however evidence of 
reduction of the anti-GAD antibody titre following the introduction of a gluten 
free diet suggesting that the diet may be beneficial in treating the condition 
(Hadjivassiliou et al., 2010c).  This finding also supports the concept of 
prevention of autoimmunity in patients with GRD if the gluten free diet is 
introduced early enough (Ventura et al., 2002). 
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 The concept of hyperexcitability of the central nervous system in the 
context of CD is of interest. We have already discussed above the entity of 
cortical myoclonus and refractory CD and the association with SPS. We have 
encountered patients with other hyperexcitable CNS disorders such as 
progressive encephalomyelitis with rigidity and spasms and patients with 
startle myoclonus who also have CD. A recent study from Italy has 
demonstrated that a group of 20 patients with newly diagnosed CD (no 
neurological complaints) had significantly shorter cortical silent period, 
reduced intracortical inhibition and enhanced intracortical facilitation by 
comparison to 20 age matched healthy controls. The authors concluded that a 
pattern of cortical excitability was found in patients with CD and that immune 
system dysregulation may be responsible for this (Pennisi et al., 2014). 
 
Pathogenesis  
Post mortem data from patients with gluten ataxia demonstrate patchy loss of 
Purkinje cells throughout the cerebellar cortex, a rather end stage non-specific 
finding in many cerebellar disorders. However, findings supporting an immune 
mediated pathogenesis include diffuse infiltration mainly of T-lymphocytes 
within the cerebellar white matter as well as marked perivascular cuffing with 
inflammatory cells (Hadjivassiliou et al., 1998). The peripheral nervous system 
also shows sparse lymphocytic infiltrates with perivascular cuffing being 
observed in sural nerve biopsy of patients with gluten neuropathy 
(Hadjivassiliou et al., 2006), in dorsal root ganglia in patients with sensory 
neuronopathy (Hadjivassiliou et al., 2010) and in patients with gluten 
myopathy (Hadjivassiliou et al., 2007). GRD patients produce an immune 
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response to gluten involving both the innate and adaptive arm of the immune 
system (Sollid and Jabri, 2009; Junker et al., 2012). Antibodies to gliadin are 
part of this response, and their systemic levels appear to mirror the immune 
reaction triggered by gluten in the intestine including their reduction in 
response to a clinical improvement of the intestinal mucosa. There is cross-
reactivity of these antibodies with antigenic epitopes on Purkinje cells. Serum 
from patients with GA and from patients with CD but no neurological 
symptoms recognize Purkinje cells of both human and rat origin 
(Hadjivassiliou et al., 2002). This reactivity can also be seen using polyclonal 
AGA and the reactivity eliminated by absorption with crude gliadin. When 
using sera from patients with GA there is evidence of additional antibodies 
targeting Purkinje cell epitopes since elimination of AGA alone is not sufficient 
to eliminate such reactivity. There is evidence that the additional antibodies 
that may be causing such reactivity, are antibodies against one or more 
transglutaminase isoenzymes (TG2, TG3, TG6) (Boscolo et al., 2010).  
 TG2 belongs to a family of enzymes that covalently crosslink or modify 
proteins through transamidation, deamidation or esterification of a peptide-
bound glutamine residue (Aeschlimann and Thomazy, 2000). Notably, the 
deamidation reaction may occur in preference over the transamidation 
reaction, even under conditions that should favour amine incorporation, and 
this appears to be substrate sequence context-dependent (Stamnaes et al., 
2008). Gluten proteins (from wheat, barley and rye), the immunological trigger 
of GRD, are glutamine rich donor substrates amenable to deamidation. 
Deamidation of gluten peptides enhances binding with disease-relevant HLAs and 
thereby enhances presentation, leading to the development of gluten-specific Th1-like 
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CD4+ T cells (Jabri and Sollid, 2009; Tye-Din et al., 2010). The resulting 
inflammatory cytokine environment drives TG2 expression through direct 
transcriptional regulation (Aeschlimann and Thomazy, 2000; Nurmiskaya and Belkin, 
2012), thereby further increasing the production of the immunological trigger. 
Therefore, Activation of TG2 and deamidation of gluten peptides appears to be 
central to disease development and is now well understood at a molecular 
level (Jabri and Sollid, 2009). In genetically predisposed individuals, this is at 
the centre of a destructive chronic inflammatory reaction manifesting as 
aphthous stomatitis in the oral cavity or villous atrophy in the upper small 
intestine at sites where the gluten load through food ingestion is high. 
 
Besides the strong gluten-specific T cell response, one of the hallmarks of 
GRD is a robust IgA autoantibody response  to TG2 or TG2 and further TG 
isozymes (Dietrich et al., 1997; Sardy et al., 2002; Hadjivassilou et al., 2008). 
Assessment of serum anti-TG2 antibodies has become an important tool in 
CD diagnosis, and new ESPGHAN guidelines enable their use as a surrogate 
marker of disease (Husby et al., 2012). However, events leading to the 
formation of autoantibodies against TG2 or other TG isozymes are less clear. 
The recent characterisation of an unusual and overwhelming immature 
plasma cell response in the small intestine goes some way to explain the strict 
association of gluten related disorders with autoantibodies to TGs (Di Niro et 
al., 2012). Notably, intestinal deposits of IgA antibodies targeting TG2 are 
present at all stages of CD, including early developing CD (Kaukinen et al., 
2005) as well as late stage refractory CD (Salmi et al.,2006) where patients 
may be seronegative. With regards to B cell activation and differentiation, the 
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hapten carrier model proposed by Sollid et al. (1997), although not formally 
demonstrated in vivo, appears to hold true, whereby gluten-specific T cells 
can provide help to TG-specific B cells. This unusual scenario is enabled by 
the ability of TGs to form stable complexes with gliadin peptides (Stamnaes et 
al., 2010) leading to uptake and ultimately presentation of MHC-gliadin 
complexes by B cells expressing TG-specific IgD. Recent in vitro studies 
confirmed that this is indeed possible (Di Niro et al., 2012). Given the relative 
lack of somatic hypermutation of the antibody repertoire present in adult 
patients that should have undergone extensive affinity maturation (Di Niro et 
al, 2012; Iversen et al., 2013), questions remain as to the mechanism by 
which B cell maturation takes place, and this could involve an extrafollicular 
pathway (Mesin et al., 2012). Plasmablasts re-enter the lamina propria via the 
circulation and form the IgA secreting plasma cell niche. It is important to keep 
in mind that B cells have roles beyond antibody production, most notably as 
highly effective antigen presenting cells for T cell responses. Therefore, B 
cells may drive clonal expansion of gluten–specific T cells which in turn may 
support development of B cells specific for TGs as well as deamidated gluten 
peptides and thereby create an amplification loop. This potentially puts B cells 
center stage of GRD pathogenesis. 
 
 Questions also remain as to the contribution of these autoantibodies to 
organ-specific deficits. Anti-TG2 antibodies have been shown to be deposited 
in the small bowel mucosa of patients with GRD and may contribute to the 
formation of the lesion. Furthermore such deposits have been found at 
extraintestinal sites, such as muscle and liver (Korponay-Szabo et al., 2004). 
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Widespread deposition of IgA antibodies has also been found around brain 
vessels in GA (Hadjivassiliou et al., 2006). The deposition was most 
pronounced in the cerebellum, pons and medulla. This finding suggests that 
such autoantibodies could play a role in the pathogenesis of the whole 
spectrum of manifestations seen in GRD and that effector functions of 
antibodies could contribute to tissue damage. IgM antibodies are present in 
GRD patients and may activate the complement cascade and promote 
inflammation.  
 Variations in the specificity of antibodies produced in individual patients 
could explain the wide spectrum of manifestations. Whilst TG2 has been 
shown to be the autoantigen in CD (Dietrich et al., 1997), the epidermal 
transglutaminase TG3 has been shown to be the autoantigen in DH (Sardy et 
al., 2002). Antibodies against TG6, a primarily brain expressed 
transglutaminase (Thomas et al., 2013), have been shown to be present in 
patients with GA (Hadjivassiliou et al., 2008). Similar to anti-TG2 and anti-
deamidated gluten peptide antibodies, the production of these anti-TG3 and 
anti-TG6 antibodies in DH and GA patients, respectively, is gluten-dependent 
which substantiates the link to a gluten-specific T cell population (Sardy et al., 
2002; Hadjivassilou et al., 2013). In GA and DH, IgA deposits of TG6 and TG3 
respectively seem to accumulate in the periphery of blood vessels at sites 
where in health the respective proteins are absent. Recent data on DH 
suggests that the deposits originate from immune complexes forming locally 
as a consequence of enhanced vascular leaking, and that TG3 although 
potentially present in health may normally be rapidely cleared (Zone et al., 
2011). Furthermore, TG3 within immune complexes retains enzymatic activity 
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and through crosslinking to fibrinogen and cell surface receptors drives innate 
immune cell activity (Taylor et al., 2015). Importantly, the demonstration that 
circulation-derived anti-TG3 antibodies can induce a dermatitis herpetiformis-
like pathology in human skin-grafted SCID mice emphasis the central role 
antibodies play in disease establishment in different organ systems (Zone et 
al., 2011). By inference, this suggests that adaptive immune cell development 
likely occurs in the gut and is not driven by trafficking of gut derived T cells to 
other organ systems. It is likely that vasculature centered inflammation is also 
at the heart of GA. Indeed perivascular cuffing with lymphocytes is a common 
finding in brain tissue from patients with GA but is also seen in peripheral 
nerve and muscle in patients with gluten neuropathy or myopathy (ref). 
However, it is unclear at present how immune complexes develop and to what 
extent a compromised blood-brain barrier is a pre-requisite to disease 
development. In most sera reactive with more than one TG isoenzyme, 
distinct antibody populations are responsible for such reactivity rather than 
this being a result of cross-reactivity with different TG isozymes 
(Hadjivassiliou et al, 2008). The absence of crossreactivity was recently 
substantiated in an analysis of clonal antibodies constituting the antibody 
repertoire in CD (Iversen et al., 2013). This makes shared epitopes less likely 
to be the cause for B cell development to other TGs and points to the 
possibility that TG isozymes other than TG2 can be the primary antigen in 
GRD. All 3 TG isozymes (TG2, TG3, TG6) for which autoantibodies have been 
described, can form thioester-linked complexes with gluten peptides which are 
thought to be responsible for the B cell response to TG isozymes (Stamnaes et al, 
2010). This implicates the shared activity of these enzymes rather than their sequence 
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similarity in stimulation of antibody production, and explains the exquisite specificity 
of the antibody response to TG family members. While antibodies targeting other 
autoantigens have been reported, the development of such antibodies is much more 
sporadic among the GRD patient population (Dieterich et al., 2006).  
 IgA deposition in brain vessels and the pathological finding of 
perivascular cuffing with inflammatory cells, may indicate that vasculature-
centred inflammation may compromise the blood-brain barrier, allowing 
exposure of the CNS to pathogenic antibodies, and therefore be the trigger of 
nervous system involvement. Indeed, TG2 is expressed by smooth muscle 
and endothelial cells in non-inflamed brain, is an abundant component of the 
choroid plexus extracellular matrix (Aeschlimann et al., 2001) and 
autoantibody binding could initiate an inflammatory response. However, 
expression of anti-TG2 antibodies in mice by themselves did not precipitate CD-like 
lesions in the small intestine or overt systemic manifestations akin of GRD (Di Niro et 
al., 2008), and no antibody deposition in brain vessels was reported. This may relate 
to the fact that it involves a specific subset of anti-TG2 antibodies that was not 
represented by the analysed clonal antibodies. It could also suggest that development 
of antibodies targeting antigens other than TG2 may be a critical step in the 
precipitation of specific extraintestinal manifestations as illustrated by anti-TG3 
antibodies in DH (Zone et al., 2011). It is also possible that additional factors other 
than the autoantibodies themselves play a role.  These may either affect vascular 
permeability, blood brain barrier integrity or antigen availability. With regards to the 
latter, TG2 and other TGs adopt a number of vastly different conformations 
dependent on biological context (Pinkas et al., 2007), and the recognition of TG2 by 
antibodies is conformation dependent (Simon-Vecsei et al., 2012; Iversen et al., 
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2013), or binding sites of TG2 may be masked in situ by other interaction partners as 
recently documented (Iversen et al., 2013). One might speculate that an unrelated 
infection or other insult that causes local inflammation may in the presence of 
circulation-derived autoantibodies bring about pathogenic immune complexes at the 
blood brain barrier. This hypothesis is consistent with experimental evidence showing 
that antibody-mediated neuronal damage in mice harbouring pathogenic antibodies 
does only occur upon compromise of the blood-brain barrier (Kowal et al., 2006). 
Furthermore, brain areas affected in experimental animals, and therefore induced 
functional deficits, differed dependent on the mechanism underlying the breach of the 
blood brain barrier (Kowal et al., 2006). It appears therefore that regionally-specific 
vascular permeability leads to localized neuronal damage. Similarly, localized 
exposure to pathogenic antibodies may explain why patients with cerebellar ataxia or 
stiff person syndrome present with similar dysfunctions affecting preferentially the 
cerebellum or spinal cord, respectively.  
 
 It could be argued that development and deposition of antibodies is an 
epiphenomenon rather than being pathogenic. One method to demonstrate 
the pathological effect of an antibody is the passive transfer of the disease 
through antibody injection into a naïve animal. While for only very few 
antibody-mediated diseases such experimental evidence exists, IgG fractions 
of patients with anti-GAD ataxia and stiff-man syndrome have been shown to 
compromise motor function and impair learning in rodents, an effect possibly 
ascribed to antibodies against GAD (Manto et al., 2007). A common problem 
in such studies is to be able to demonstrate whether it is these specific 
antibodies or other autoantibodies in the IgG-fraction of patient sera that 
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cause neuronal damage. Using a mouse model we have recently shown that 
serum from GA patients as well as clonal monovalent anti-TG 
immunoglobulins derived using phage display, cause ataxia when injected 
intraventricularly in mice (Boscolo et al., 2010).  The fact that not only Ig 
fractions but also monospecific scFv’s mediate functional deficits shows that 
there is no requirement for complement activation or for the engagement of Fc 
receptors on Fc-receptor bearing cells in the brain. These data therefore 
provide evidence  that anti-TG immunoglobulins (derived from patients) 
compromise neuronal function in selected areas of the brain once exposed to 
the CNS and suggest that this involves an immune system independent mode 
of action.  
 
A bias of the immune response towards TG6 in GRD patients presenting with 
neurological deficits (Hadjivassiliou et al., 2008, 2013) implicates neuronal 
TG6 in pathogenesis, at least of GA but possibly also other neurological 
problems. Further support for this notion comes from the identification of 
mutations in the gene encoding TG6 in families with autosomal dominant 
ataxia (Wang et al., 2010; Li et al., 2013). This form of spinocerebellar ataxia 
is now referred to as SCA35. Clinical features associated with TGM6 
mutations are those of late onset cerebellar ataxia, slow progression of gait 
and limb ataxia, hyperreflexia, and cerebellar degeneration but with no 
cognitive impairment, autonomic and peripheral nerve involvement, or 
epilepsy (Wang et al., 2010; Li et al., 2013). This is in keeping with the 
presentation in patients with immune-mediated cerebellar ataxia (GA), and 
provides strong evidence for an essential function of TG6 in the CNS. TG6 is, 
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however, expressed by other cells including various epithelia (Thomas et al., 
2013), and one of the TGM6 mutations also associated with acute myeloid 
leukemia (Pan et al., 2014). Functional data on the physiological role of TG6 
protein are sparse at present. We have begun to characterise the enzyme 
biochemically and analyse the gene expression pattern during development, 
which identified a complex system with splice variants that are differentially 
expressed and presumably functionally distinct (Thomas et al., 2013). Using 
molecular modeling and biochemical assays, we have shown that TG6 is 
regulated by GTP and Ca2+ similar to TG2, and adopts compact or extended 
conformations with transamidation activity, respectively (Thomas et al. 2013). 
The expression of TG6 during CNS development demonstrated an 
association with neurogenesis, and this was further confirmed by in vitro 
differentiation of neuronal precursor cells (Thomas et al., 2013). All single 
nucleotide exchanges reported to date lead to alteration of amino acid 
residues that are strictly conserved in TG6 among different species. Based on 
structural modeling and biochemical analysis (Thomas et al., 2013), we 
hypothesise that the biological significance of TGM6 mutations lies in the 
impairment of regulation of transamidation activity. This implicates TG6 in an 
extracellular function that is critical to neuronal differentiation and survival. 
However, how crosslinking or modification of extracellular proteins    
contributes to neuronal survival remains to be identified. Autoantibody binding 
may sequester TG6 or block its activity and thereby act as a competitive 
inhibitor of enzyme function.  
 
Conclusions  
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 GRD include immune mediated diseases triggered by ingestion of 
gluten proteins. While coeliac disease has been the most comprehensively 
studied of all GRD, to fully understand the immunological aftermath from 
gluten ingestion, there is a need to further study extraintestinal manifestations. 
In addition there is a need for the early identification of those patients that are 
specifically at risk of irreversible complications (eg gluten ataxia). To that 
effect, new diagnostic tools are now becoming available (e.g. antibodies 
against TG6) which may make a more reliable identification of those patients 
with neurological manifestations a reality. Up to 40% of patients presenting to 
the gastroenterologist who are ultimately diagnosed with CD also have 
antibodies against TG6 in addition to antibodies against TG2. This subgroup 
of patients with classic CD presentation may well be the ones susceptible to 
the development of neurological dysfunction if they continue to consume 
gluten, although this remains to be shown in longitudinal studies. The 
presence of gastrointestinal symptoms, however, offers a major potential 
advantage to this group, as it substantially increases their chances of being 
diagnosed and treated early, whereas the diagnosis of those patients 
presenting purely with extraintestinal manifestations may be more difficult.  
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